Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladdercancerA shortage of BCG is foreseen till the end of 2013.Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available?In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice isradical cystectomy. Device-assisted therapies, although showing promising results, should be consideredonly for selected patients.In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG isavailable. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferablypreceded by early instillation, according to the EAU guidelines.
|Numero di pagine||3|
|Stato di pubblicazione||Published - 2013|
All Science Journal Classification (ASJC) codes